Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination chemoradiotherapy with gemcitabine: potential applications.

H Choy1

  • 1Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Oncology (Williston Park, N.Y.)
|August 29, 2000
PubMed
Summary

Gemcitabine (Gemzar) shows potential as a radiosensitizer for non-small-cell lung cancer. Further clinical trials are necessary to determine optimal dosing, toxicity, and efficacy for this promising chemotherapy and radiation combination.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine.

Lung cancer (Amsterdam, Netherlands)·2005
Same author

A phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non small-cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial.

Clinical lung cancer·2004
Same author

Topoisomerase I inhibitors in the combined modality therapy of lung cancer.

Clinical lung cancer·2004
Same author

A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

Clinical lung cancer·2004
Same author

Management of unresectable non-small cell carcinoma of the lung (NSCLC).

Lung cancer (Amsterdam, Netherlands)·2004

Area of Science:

  • Oncology
  • Pharmacology
  • Radiation Oncology

Background:

  • Gemcitabine (Gemzar) is a novel deoxycytidine analog.
  • It exhibits promising single-agent activity in non-small-cell lung cancer (NSCLC).
  • Gemcitabine is recognized as a potent radiosensitizer.

Purpose of the Study:

  • To review clinical trials evaluating gemcitabine in combination with radiation therapy.
  • To explore the potential of gemcitabine as a radiosensitizing agent in NSCLC treatment.
  • To summarize current understanding of gemcitabine's role in combined modality treatment.

Main Methods:

  • Review of clinical trials investigating gemcitabine and radiation therapy.
  • Analysis of studies focusing on gemcitabine's proposed mechanisms of radiosensitization, including deoxyadenosine triphosphate (dATP) pool depletion and cell-cycle manipulation.

Related Experiment Videos

  • Evaluation of various dosing schedules and treatment combinations.

    • Main Results:

    • Gemcitabine demonstrates radiosensitizing properties in preclinical and clinical settings.
    • Several trials have explored combining gemcitabine with radiation therapy for NSCLC.
    • The precise mechanism of gemcitabine's radiosensitizing effect requires further elucidation.

    Conclusions:

    • Gemcitabine is a promising agent for combination with radiation therapy in NSCLC.
    • Optimal doses, toxicity profiles, and efficacy require further definition through ongoing clinical trials.
    • Additional research is essential to fully establish gemcitabine's role in lung cancer treatment.